Supporting Companies Supporting People

Your trusted advisor in the mental health and psychedelics space, committed to investing in true innovation.
Apply now

Accelerator Program

Our accelerator program is designed to help early and mid-stage companies grow and thrive, providing them with the resources, mentorship, and support they need to succeed. From capital formation and marketing to product development and team-building, we work closely with our portfolio companies to help them overcome challenges and achieve their goals.


At the Psychedelic Vision Fund, we take great care in selecting investment opportunities. Our selection criteria are based on a number of factors, including the potential impact of the company on mental and emotional health, the quality of the team, and the potential for growth and success.  


In addition to our accelerator program, we also offer consulting services to companies in the mental and emotional well-being space. Whether you are looking for advice on strategy, capital formation, or product development, our team of experts can provide the guidance and support you need to succeed.

Submit Your Company For Consideration



Our Team

Our team of experts includes experienced entrepreneurs, investors, and consultants, who bring a wealth of knowledge and experience to the process. We are passionate about empowering companies that share our values and are committed to making a positive impact on the world.


Our Approach

Psychedelics Vision is a unique and dynamic organization that is dedicated to accelerating growth and success for companies in the mental and emotional well-being space, with a special focus on those leveraging psychedelic therapies. At our core, we believe in the profound potential of psychedelics to transform the way we approach mental and emotional health. 

We’ve built a library of playbooks and tools to help founders reach product-market fit more efficiently and avoid wasting their valuable runway. 


Our Values

We are committed to upholding the highest standards of ethics and values in everything we do. We believe in transparency, honesty, and integrity, and we strive to build long-term relationships with our portfolio companies and advisory clients based on mutual trust and respect. 

Why Now?

At Psychedelic Vision Fund, we recognize that the mental and emotional well-being industry is currently facing distressing challenges and uncertainties. However, we firmly believe that in times of crisis, there is also a great opportunity for growth and innovation.

As experienced entrepreneurs and investors, we understand the challenges that businesses in this phase of the economic-cycle face. Other industries have been here before and some have overcome the obstacles. We are committed to using our expertise to guide our portfolio companies and advisory clients through these challenging times.

Our goal is not only to help businesses survive in this market but to thrive and emerge stronger. We believe that by working together, we can create innovative solutions and drive positive change in the mental and emotional well-being industry.

We are committed to using our resources, networks, and experience to help keep well-intentioned and high growth potential companies alive and thriving, while also helping them explore new opportunities for growth and expansion. Our team has a deep understanding of the unique needs and challenges of this market, and we are dedicated to providing tailored support and guidance to all of our business partners.


Addressable Industry Challenges

If you are working to solve any of these identified areas of challenge for the industry, we want to hear from you.

Regulatory challenges: The use of psychedelic therapies for mental health treatment is still largely unregulated in most countries, which creates a number of challenges for companies trying to develop and market these therapies.

Lack of research and clinical data: While there is a growing body of research suggesting that psychedelic therapies can be effective for treating a range of mental health conditions, there is still much that is unknown, such as the role of belief or placebo in outcomes. This lack of data can make it difficult for companies to gain regulatory approval and for clinicians to feel comfortable using these therapies.

Stigma and social acceptance: Psychedelic therapies still face a great deal of stigma and controversy, which can make it challenging for companies to gain public acceptance and investment.

High cost of care: Psychedelic-assisted therapy can be expensive, and many people cannot afford it. This creates a barrier to access for those who have the largest need for treatment. Additionally, insurance coverage for psychedelic therapy is limited, making it difficult for many to receive the care they need.

Intellectual property challenges: With so much innovation happening in the psychedelic mental health industry, there are a number of intellectual property challenges emerging, including disputes over patents and ownership of research.

Diversity and inequality: There is a growing concern about the lack of diversity and representation in clinical trials and psychedelic care, with marginalized communities and those of lower socioeconomic status being disproportionately impacted by mental health issues and at increased risk of being unable to access these therapies.

Safety concerns: Psychedelic therapies can be powerful tools, but they are not without risks. Ensuring the safety of patients and clinicians during these therapies is a top priority for the industry, and best practices and regulations are needed to minimize risk.

Unknowns: Limited understanding of why some individuals do not respond or respond adversely to treatment.

Potential harm: Risk of inducing psychosis or an unmanageable spiritual emergence in some individuals during and after treatment.

Misaligned incentives: Corporate models prioritizing shareholder return over the quality of client care or the well-being of all stakeholders involved in care delivery and in local communities. 

Contact us

14 + 14 =

"Psychedelics are tools for exploring the deep mysteries of consciousness, but they are not the answer to those mysteries. The ultimate truth lies within us, waiting to be discovered."

–  Albert Hofmann.

Source: “LSD: My Problem Child.”

"The role of psychedelics in our culture is to catalyze the emergence of the new archaic revival, the transcendence of linear consciousness, and the embrace of simultaneous awareness."

– Terence McKenna.

Source: “Food of the Gods: The Search for the Original Tree of Knowledge.”

"Psychedelics are not a substitute for faith or spiritual practice. They are a catalyst for awakening and transformation, but the work of integration and embodiment must still be done."

– Stanislav Grof.

Source: “The Holotropic Mind: The Three Levels of Human Consciousness and How They Shape Our Lives.”

"The psychedelic experience is a journey to the center of the self, where we discover that we are all one and interconnected with the universe."

– Timothy Leary.

Source: “The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead.”

"Psychedelics are not just drugs, they are medicines for the soul. They can heal the wounds of the past and open us up to the possibilities of the future."

– Jack Kornfield.

Source: “After the Ecstasy, the Laundry: How the Heart Grows Wise on the Spiritual Path.”

"Psychedelics are a tool for exploring the unknown, but they are not a shortcut. The journey is long and difficult, but the rewards are profound and life-changing."

– Daniel Pinchbeck.

Source: “Breaking Open the Head: A Psychedelic Journey into the Heart of Contemporary Shamanism.”

Our Office

Psychedelics Vision Fund       475 Washington Blvd.        Marina Del Rey, CA 90292

Contact Us


Office Hours

Mon-Fri: 9am – 5pm PST
Sat-Sun: Closed

Follow Us